Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pilot study of raltegravir augmentation on persistent central nervous system (CNS) immunoactivation in treated HIV-1 patients

Trial Profile

Pilot study of raltegravir augmentation on persistent central nervous system (CNS) immunoactivation in treated HIV-1 patients

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Dec 2015

At a glance

  • Drugs Raltegravir (Primary) ; Antiretrovirals
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 16 Feb 2010 Substudy results assessing viraemia in cerebrospinal fluid presented at the 17th Conference on Retroviruses and Opportunistic Infections.
    • 27 May 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top